WCI1680-09: Evaluation of Alterations in Time of Administration of Plerixafor (Mozobil ®, AMD3100) in Combination With G-CSF on Safety and CD34+ Cell Mobilization
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the proportion of patients who collect ≥ 5 x 106 CD34+ cells by day 5 (4 apheresis sessions) with plerixafor administration at 1500 and compare to historical data with administration at 2200.
Within the first 5 days following plerixafor initiation
R. Donald Harvey, PharmD, FCCP
Emory University Winship Cancer Institute
United States: Institutional Review Board
|Emory University Winship Cancer Institute||Atlanta, Georgia 30322|